Section Review: Cardiovascular & Renal: Changing insights in the drug treatment of congestive heart failure

References

• PACKER M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. (1992) 20:248–254.
   PubMed Web of Science ®Google Scholar
• PACKER M: Pathophysiology of chronic heart failure. Lancet (1992) 340:88–91.
   PubMed Web of Science ®Google Scholar
• PACKER M: How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am. J. Cardiol. (1993) 71:3C–11C.
   Google Scholar
• VAN ZWIETEN PA, LIE KI: Neuroendocrine compensa- tory mechanisms as a target for the drug treatment of congestive heart failure. Cardiology (1994) 1:311–320.
   Google Scholar
• RITZ E, FLISER D: The kidney in congestive heart failure. Eur. Heart J. (1991) 12(Suppl. C):14–20.
   Google Scholar
• PACKER M: Treatment of chronic heart failure. Lancet (1992) 340:92–95.
   PubMed Web of Science ®Google Scholar
• VAN ZWIETEN PA: Neuroendocrine effects of diuretics In heart failure. Br. Heart" (1994) 72:51–53.
   Google Scholar
• FRANCIS GS, SIEGEL RM, GOLDSMITH SR, OLIVARI MT,LEVINE TB, COHN JN: Acute vasoconstrictor response to Intravenous furosemicle in patients with chronic con-gestive heart failure. Activation of the neuro-humoral axis. Ann. Intern. Med. (1985) 103:1–6.
   PubMed Web of Science ®Google Scholar
• BAYLISS J, NORELL M, CANEPA-ANSON R, SUTTON G,POOLE-WILSON P: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br. Heart J. (1987) 57:17–22.
   PubMedGoogle Scholar
• GOLDSMITH SR, FRANCIS G, COHN JN: Attenuation of the pressor response to intravenous furosemide by angiotensin converting enzyme inhibition in conges-tive heart failure. Am.J. Cardiol. (1989) 64:382–385.
   Web of Science ®Google Scholar
• WARD A, HEEL RC: Bumetanide. A review of its pharma-codynamic and pharmacokinetic properties and thera-peutic use. Drugs (1984) 28:426–464.
   Google Scholar
• CLISSOLD SP, BROGDEN RN: Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs (1985) 29:489–530.
   Google Scholar
• BRATER DC: Clinical pharmacology of loop diuretics.Drugs (1991) 41\(Suppl. 3):14–22.
   Google Scholar
• DI BIANCO R, SHABETAI R, KOSSUK W, MORAN J, SCHLANT RC, WRIGHT R: A comparison of oral milri-none, digoxin and their combination in the treatment of patients with chronic heart failure. New Engl. J. Med. (1989) 320:677–683.
   PubMed Web of Science ®Google Scholar
• PACKER M, GHEORGIADE M, YOUNG JB, CONSTANTINI PJ, ADAMS KF, CODY RJ, ET AL.: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converlIng-enzyme inhibitors. New Engl. J. Med. (1993) 329:1–7.
   Google Scholar
• FERGUSON DW, BERG WJ, SANDERS JS, ROACH PJ, KEMPF JS, KIENZLE MG: Sympatho-inhibitory responses to digi-talis glycosides in heart faihwe patients. Direct evidence from sympathetic neural recordings. Circulation (1989) 80:65–77.
   Google Scholar
• FERGUSON DW: Sympathetic mechanisms in heart fail- ure. Pathophysiological and pharmacological implica-tions. Circulation (1993) 87(Suppl. VII):68–75.
   Google Scholar
• VAN VELDHUISEN DJ, MAN IN 'T VELD AJ, DUNSELMAN PHJM, LOK DJA, DOHMEN HJM, POORTERMANS JV, ETAL.: Double-blind, placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure. Results of the Dutch lbopamine Multicentre Trial (MKT). J. Am. Coll. Cardiol. (1993) 22:1564–1573.
   Google Scholar
• VAN ZWIETEN PA: Receptor-mediated inotropic drugs. Eur. Heart J. (1988) 9(Suppl.
   Google Scholar
• COHN JN, ARCHIBALD DG, ZIESCHE S, FRANCIOSA JA, HARSTON WE: Effect of vas odilator therapy on mortality In chronic congestive heart failure: results of a Veterans Administration Co-operative Study (V-HEFT). New Engl. J. Med. (1986) 314:1547–1552.
   PubMed Web of Science ®Google Scholar
• FRANCIS GS, COHN JN, JOHNSON G, RECTOR TS, GOLD- MAN S, SIMON A: Plasma norepinephrine, plasma renin activity and congestive heart failure relations to sur-vival and the effects of therapy in V-HEFT U. Circulation (1993) 87(Suppl. V0:40–48.
   Google Scholar
• MCGRATH BP, ARNOLDA L, MATTHEWS PG, JACKSON B,JENNINGS G, ICIAT H, ET AL.: Controlled trial of enalapril In congestive heart failure. Br. Heart.J. (1985) 54:405–414.
   Google Scholar
• COHN JN: The prevention of heart failure anew agenda.New Engl. J. Med. (1992) 327:725–727.
   PubMed Web of Science ®Google Scholar
• VAN WOERKENS LJ, BOOMSMA F, MAN IN 7 VELD AJ,BEVERS MM, VERDOUW PD: Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor block-ade. Br. J. Pharmacol. (1992) 107:303–310.
   PubMed Web of Science ®Google Scholar
• BRAVO G, GHYSEL-BURTON J, JAUMIN P, GODFRAIND T: A comparison of the inotropic effects of dopamine and epinine in human isolated cardiac preparations. J. Pharmacol. Exp. Ther. (1991) 257:439–443.
   PubMed Web of Science ®Google Scholar
• VAN VELDHUISEN DJ: lbopamine in heart failure. Effi-cacy and safety in clinical and experimental studies [dissertation]. Groningen: Rijksuniversiteit Groningen (1993):20–29, 116–140.
   Google Scholar
• VAN VELDHUISEN DJ, CRIJNS HJ, GIRBES ARJ, TOBE JM, WIESFELD ACP, LIE KU Electrophysiologic profile of ibopamine in patients with congestive heart failure and ventricular tachycardia and relation to its effects on hemodynamics and plasma catecholamines. Am. J. Cardiol. (1991) 68:1194–1202.
   PubMed Web of Science ®Google Scholar
• GIRBES ARJ, ICALISVAART CJ, VAN VEIDHULSEN DJ, SMITAJ, PASTEUNING WH: Effects of ibopamine on renal haemodynamics in patients with severe congestive heart failure. Eur. Heart. J. (1993) 14:279–283.
   PubMed Web of Science ®Google Scholar
• DEI CAS L, MEFRA M, VISIOLI O: Effects of acute andchronic ibopamine administration on resting and ex-ercise hemodynamics, plasma catecholamines and functional capacity of patients with chronic congestive heart failure. Am. J. Cardiol. (1992) 70:629–634.
   PubMed Web of Science ®Google Scholar
• HEILBRUNN SM, SHALT P, BRISTOW MR, VALENTINE HA,MULLIN AV, GINSBERG R, ET AL.: Increased [3-receptor density and improved hemodynamic response to cate-holamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation (1989) 79:483–490.
   Google Scholar
• PACKER M: Pathophysiological mechanisms underlyingthe effects of 13-adrenergic agonists and antagonists on functional capacity and survival in chronic heart fail-ure. Circulation (1990) 82\(Suppl. 1):177–188.
   Google Scholar
• PERSSON H, ERHARDT L: Beta receptor antagonists inthe treatment of heart failure. Cardiovasc. Drugs. 713er. (1991) 5:589–604.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, HERSHBERGER RE, PORT JD, GILBERT EM, SANDOVAL A, RASMUSSEN R, ET AL.: P-Adrenergic path-ways in non-failing human ventricular myocardium. Circulation (1990) 82\(Suppl. 1):112–125.
   Google Scholar
• BRODDE OE: pi- and [32-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev. (1991) 43:203–242.
   PubMed Web of Science ®Google Scholar
• PACKER M: Role of the sympathetic nervous system in of.chronic heart failure. Circulation (1990) 82\(Suppl. 1):11–16.
   Google Scholar
• ANDERSON JL, LUTZ JR, GILBERT EM, SORENSON SG, YANOWITZ FG, MENLOVE RI, ET AL.: A randomised trial of low dose 13-blockade therapy for idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1985) 55:471–475.
   Google Scholar
• HJALMARSON A, WAAGSTEIN F: The role of13-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs (1994) 47\(Suppl. 4):31–40.
   Google Scholar
• PANFILOV V, WAHLQVIST I, OLSSON G: Use of beta-ad-renoceptor blockers in patients with congestive heart failure. Cardiovasc. Drugs Ther. (1995) 9:273–287.
   PubMed Web of Science ®Google Scholar
• REICHER-REISS H, BARASCH E: Calcium antagonists in patients with heart failure. Drugs (1991) 42:343–364.
   PubMed Web of Science ®Google Scholar
• COHN JN: Personal communication.
   Google Scholar
• CLOZEL JP, VENIANT M, OSTERRIEDER W: The structur-ally novel Ca2*-channel blocker Ro 40-5967, which binds to the [311]-des-methoxy-verapamil receptor, is devoid of the negative inotropic activity of verapamil In normal and failing rat hearts. Cardiovasc. Drugs Ther. (1990) 4:731–736.
   PubMed Web of Science ®Google Scholar
• PORTEGIESS MCM, SCHMITT R, KRAAIJ CJ: Lack of nega-tive inotropic effects of the new caldutn antagonist Ro 40-5967 in patients with stable angina pectoris. J. Cardiovasc. Pbarmacol. (1991) 18:746–751.
   PubMed Web of Science ®Google Scholar
• CONSENSUS TRIAL GROUP: Effects of enalapril on mor- talky in severe congestive heart failure. New Engl.J. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• SOLVD INVESTIGATORS: Effect of enalapril on survivalIn patients with reduced left ventricular ejection frac-tions and congestive heart failure. New EngL J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• HELD P, SWEDBERG K: ACE inhibitors in the treatmentof heart failure. In: Congestive Cardiac Failure. Barnett DB (Ed.). Dekker, New York (1993):169–183.
   Google Scholar
• COHN JN, JOHNSON G, ZLESCHE S, COBB F, FRANCIS G, TRISTANI F: A comparison of enalapril with hy-dralazine-isosorbide dinitrate in the treatment of con-gestive heart failure. New Engl.J. Med. (1991) 325:303–310.
   PubMed Web of Science ®Google Scholar
• INAGAMI T, KITAMI Y: Angiotensin H-receptors: molecu-lar cloning functions, and regulation. Hypertens. Res. (1994) 17:87–97.
   Google Scholar
• TIMMERMANS PBMWM, SMITH RD: Angiotensin II-recep-tor subtypes: Angiotensin II-receptor subtypes and functional correlates. Eur. HeartJ. (1994) 15(Suppl. D):79–87.
   Google Scholar
• MACFADYEN RJ, REID JL: Angiotensin receptor antago-nists as a treatment for hypertension. J. Hypertens. (1994) 12:1333–1338.
   PubMed Web of Science ®Google Scholar
• HUSAIN A: The chymase-angiotensin system in humans. Hypertension (1993) 11:1155–1159.
   Web of Science ®Google Scholar
• LACOURCIEFtE Y, BRUNNER H, IRWIN R, KARLBERG BE, RAMSAY LE, SNAVELY DB, ET AL.: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J. Hypertens. (1994) 12:1387–1393.
   Google Scholar
• CROZIER I, IKRAM H, AWAN N, CLELAND J, STEPHEN N, DICKSTEIN K, ET AL Losartan in heart failure. Hemodynamic effects and tolerability. Circulation (1995) 91:691–697.
   PubMed Web of Science ®Google Scholar
• RAINE A, ERNE P, BURGISSER E: Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. New Engl.J. Med. (1986) 315:533–537.
   PubMed Web of Science ®Google Scholar
• ELSNER D, MONTZE A, KROMER EP, RIEGGER AJ: Effec-tiveness of endopeptirI2se inhibition (candoxatril) in congestive heart failure. Am.J. Cardiol. (1992)70:494–498.
   PubMed Web of Science ®Google Scholar
• MUNZEL T, KURZ S, HOLTZ J, BUSSE R STEINHAUER H, JUST H, DREXLER H: Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation (1992) 86:1089–1098.
   PubMed Web of Science ®Google Scholar
• CREAGER MA, FAXON DP, CUTLER SS, KOHLMANN O, RYAN TJ, GAVRAS H: Contribution of vasopressin to vasoconstriction in patients with congestive heart fail-ure: comparison with the renin-angiotensin system and the sympathetic nervous system. J. Am. Coll. Cardiol. (1986) 7:758–765.
   PubMed Web of Science ®Google Scholar
• NICOD P, WAEBER B, BUSSIEN JP, GOY JJ, TURINI G,NUSSBERGER J, ET AL.: Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure. Am. J. Cardiol. (1985) 55:1043–1047.
   Google Scholar
• MULINARI RA, GAVRAS I, WANG YX, KOHLMANN O, GAVRAS H: Effects of a vasopressin antagonist with combined antipressor and antidiuretic activities in rats with left ventricular dysfunction. Circulation (1990) 81:308–311.
   PubMed Web of Science ®Google Scholar
• PACKER M, CARVER JR, RODEHEFFER RJ, IVANHOE RJ, DIBIANCO R, ZELDIS SM, ETAL., FOR THE PROMISE STUDY RESEARCH GROUP: Effect of oral mikinone on mortality In severe chronic heart failure. New Engl. J. Med. (1991) 325:1468–1475.
   Google Scholar
• VAN MEEL JCA: Cardiovascular effects of the positive inotropk agents pimobendan and suhnazole in vivo. Arzneim.-Forsch . (1985) 35:284–288.
   PubMed Web of Science ®Google Scholar
• RUEGG JC: Effects of new inotropic agents on Ca2+-sen-sitivity of contractile proteins. Circulation (1986) 73(Suppl.
   Google Scholar
• NANKERVIS R, LUES I, BROWN L: Calcium sensitization as a positive inotropic mechanism in diseased rat and human heart. J. Cardiovasc. Pharmacol. (1994) 24:612–617.
   PubMed Web of Science ®Google Scholar
• REMME WJ, KRUIJSSEN DACM, VAN HOOGENHUYZE X, KRAUS H, BARTELS CJ, STORM CJ, DE LEEUW PW: Hemodynamic, neurohonnonal, and myocardial ener-getic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. J. Cardiovasc. Pharmacol. (1994) 24:730–739.
   PubMed Web of Science ®Google Scholar
• REMME \VJ, KRAYENBOHL HP, BAUMANN G, FRICK MH, HAEHL M, NEHMIZ G, BAIKER W: Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind comparison with enalapriL Eur. Heart J. (1994) 15:947–956.
   Google Scholar
• HAGEMEIJER F: Calcium sensitization with pimoben-dart: pharmacology, haemodynarnir improvement, and sudden death in patients with chronic congestive heart failure. Eur. Hear1J. (1993) 14:551–566.
   Google Scholar
• YAMASHITA S, HOSOKAWA T, KOJIMA M, MORI T, YABUUCHI Y: In vitro and in vivo studies of 3,4-dihy-dro-6- [4 - (3,4 - dimethoxy-benzoyi) - 1 - piperaziny1]-2(1H)-quinolinone (OPC 8212), a novel positive inotropic drug in various animals. Arzneim.-Forsch. (1984) 34:342–346.
   PubMedGoogle Scholar
• BUSCH FW, T1LLMANN A, BECKER EW, OWSIANOWSKI M, BERG PA: The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-644-(3,4-di-methoxybenzoy1)-piperazyny1]-2(1H)-quinolinone (OPC 8212), on bone-marrow progenitor cells and peripheral lymphocytes. Eur. J. Clin. Pharrnacol. (1992) 42:629–633.
   PubMedGoogle Scholar
• FELDMAN AM, BRISTOW MR, PARMLEY WW, CARSON PE, PEPINE CJ, ET AL.: Effects of vesnarinone on morbidity and mortality in patients with heart failure. New Engl. J. Med. (1993) 329:149–155.
   Google Scholar